These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1052 related items for PubMed ID: 24565519

  • 1. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
    Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z, Mei X.
    Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
    [Abstract] [Full Text] [Related]

  • 2. Dual stimulus of hyperthermia and intracellular redox environment triggered release of siRNA for tumor-specific therapy.
    Yang Y, Yang Y, Xie X, Xu X, Xia X, Wang H, Li L, Dong W, Ma P, Liu Y.
    Int J Pharm; 2016 Jun 15; 506(1-2):158-73. PubMed ID: 27106526
    [Abstract] [Full Text] [Related]

  • 3. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery.
    Lin W, Xie X, Deng J, Liu H, Chen Y, Fu X, Liu H, Yang Y.
    J Drug Target; 2016 Jun 15; 24(2):134-46. PubMed ID: 26176270
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
    Yang Y, Yang Y, Xie X, Wang Z, Gong W, Zhang H, Li Y, Yu F, Li Z, Mei X.
    Biomaterials; 2015 Apr 15; 48():84-96. PubMed ID: 25701034
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intelligent "Peptide-Gathering Mechanical Arm" Tames Wild "Trojan-Horse" Peptides for the Controlled Delivery of Cancer Nanotherapeutics.
    Shi NQ, Li Y, Zhang Y, Shen N, Qi L, Wang SR, Qi XR.
    ACS Appl Mater Interfaces; 2017 Dec 06; 9(48):41767-41781. PubMed ID: 29161013
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
    Takara K, Hatakeyama H, Kibria G, Ohga N, Hida K, Harashima H.
    J Control Release; 2012 Aug 20; 162(1):225-32. PubMed ID: 22728515
    [Abstract] [Full Text] [Related]

  • 15. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
    Deshpande P, Jhaveri A, Pattni B, Biswas S, Torchilin V.
    Drug Deliv; 2018 Nov 20; 25(1):517-532. PubMed ID: 29433357
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes.
    Dicheva BM, ten Hagen TL, Schipper D, Seynhaeve AL, van Rhoon GC, Eggermont AM, Koning GA.
    J Control Release; 2014 Dec 10; 195():37-48. PubMed ID: 25176578
    [Abstract] [Full Text] [Related]

  • 18. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA, Abnous K, Badiee A, Jaafari MR.
    Colloids Surf B Biointerfaces; 2016 Mar 01; 139():228-36. PubMed ID: 26722819
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.